PharmaCyte Biotech, Inc. PMCB PHARMA

Q: What is the current share price of PharmaCyte Biotech, Inc. (PMCB)?

As of 2026-09-19 21:16 PDT, PharmaCyte Biotech, Inc. (PMCB) trades at $0.49 on NasdaqCM. Its 52-week range is $0.48 to $1.22.

Q: What is the market capitalisation of PMCB?

PharmaCyte Biotech, Inc. (PMCB) has a market capitalisation of $5.26M on NasdaqCM.

Q: What is the P/E ratio of PMCB?

PMCB trades at a trailing price-to-earnings (P/E) ratio of -0.24. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.43.

Q: What is the return on equity (ROE) of PMCB?

PMCB has a return on equity (ROE) of -43.99%. Its return on capital employed (ROCE) is -14.92%.

Q: Is PMCB a good stock to buy?

This page provides a data-driven analysis of PharmaCyte Biotech, Inc. (PMCB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://pharmacyte.com

Company Profile ↓

$0.49

-42.47% 1Y

Mkt Cap$5.26M

P/E-0.24

P/B0.43

52W High$1.22

52W Low$0.48

Book Value$1.07

EPS (TTM)$-2.08

Company Overview

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Trailing 12 Months Year-on-year growth — earnings -163.4%.

Growth & Price Performance

Compounded Profit Growth

5 Years:	-
1 Year:	-163.36%

Stock Price Performance

1 Year:	-42.47%
6 Months:	-30.15%
3 Months:	-30.14%
1 Month:	-17.13%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 1% of range

$0.48 $1.22

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)32.21 · Neutral

Price Performance

1M-17.13%

3M-30.14%

6M-30.15%

1Y-42.47%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.

CONS

Trading 59.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.24

Industry PE

24.83

Forward P/E

-1.29

PEG Ratio

Book Value

$1.07

Price to Book

0.43

P/S

EV/EBITDA

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

Earnings (YoY)

-163.36%

Profitability & Returns

ROCE

-14.92%

ROE

-43.99%

ROA

-8.35%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.17

EPS (TTM)

$-2.08

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

40.25

Current Ratio

40.30

Debt

Total Assets

$46.75M

Current Assets

$20.70M

Working Capital

$21.55M

Ownership

Promoter Holding

5.74%

Chg in Prom Hold

0.00%

FII / Inst Holding

7.11%

Chg in FII Hold

-1.89%

Financial Snapshot

Enterprise Value

$5.26M

Total Revenue (TTM)

EBITDA

$-4.38M

Free Cash Flow

$2.63M

Operating Cash Flow

$-3.94M

Shares Outstanding

10.74M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PMCB PharmaCyte Biotech, Inc. PHARMA	0.49	-0.24	$5.26M	0.00%	-14.92%	-43.99%	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jul 2014	Oct 2014	Jan 2015	Apr 2015	Jul 2015	Oct 2015	Jan 2016	Apr 2016	Jul 2016	Oct 2016	Jan 2017	Apr 2017	Jul 2017	Oct 2017	Jan 2018	Jul 2018	Oct 2018	Jan 2019	Jul 2019	Oct 2019	Jan 2020	Jul 2020	Oct 2020	Jan 2021	Jul 2021	Oct 2021	Jan 2022	Jul 2022	Oct 2022	Jan 2023	Jul 2023	Oct 2023	Jan 2024	Jul 2024	Oct 2024	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	960.25K	1.04M	848.30K	1.38M	2.12M
Operating Income	-1.58M	-6.25M	-1.46M	-	-1.51M	-1.64M	-1.79M	-	-1.03M	-974.20K	-1.28M	-	-1.69M	-1.81M	-2.03M	-1.22M	-1.04M	-676.35K	-1.13M	-1.07M	-875.31K	-881.68K	-949.51K	-756.85K	-1.02M	-1.00M	-856.12K	-1.68M	-2.32M	-1.55M	-2.08M	-1.41M	-1.87M	-1.27M	-1.11M	-960.25K	-1.04M	-848.30K	-1.38M	-2.12M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-960.25K	-1.04M	-848.30K	-1.38M	-2.12M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.05M	11.75M	-8.36M	-7.42M	746.86K
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.58M	-2.86M	-1.46M	-4.02M	-1.52M	-1.64M	-1.79M	-1.12M	-1.03M	-974.55K	-1.28M	-1.16M	-1.69M	-1.81M	-2.03M	-1.22M	-1.04M	-676.35K	-1.13M	-1.07M	-875.31K	-883.94K	-950.19K	-757.10K	-1.03M	-979.75K	-811.29K	-1.55M	-1.88M	-764.14K	-3.18M	2.79M	-619.54K	23.42M	-1.47M	-3.05M	11.75M	-8.36M	-7.42M	746.86K
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.64	-0.06	-0.04	-0.07	-0.09	-0.04	-0.54	-0.26	-0.65	1.90	-0.39	-0.44	-	-1.23	-1.24	-0.17
R&D Expense	0	347.76K	273.80K	-	155.68K	439.71K	573.98K	-	175.00K	253.77K	579.72K	-	427.67K	515.46K	802.56K	267.79K	115.10K	59.14K	72.33K	17.94K	113.30K	270.57K	151.31K	174.09K	143.61K	135.22K	158.04K	159.27K	178.00K	45.39K	104.48K	82.03K	126.73K	96.02K	97.47K	118.20K	-	95.16K	141.09K	93.11K

Profit & Loss (Annual)

Figures in USD.

Metric	Apr 2011	Apr 2012	Apr 2013	Apr 2014	Apr 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025	Apr 2026
Revenue	126.00K	66.56K	12.16K	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	93.89K	47.17K	2.54K	0	0	0	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	4.39M	6.46M	6.52M	4.38M	-
Operating Income	-	-1.95M	-1.68M	-18.98M	-13.26M	-6.07M	-4.44M	-6.98M	-4.10M	-3.83M	-3.62M	-4.39M	-6.46M	-6.52M	-4.38M	-6.85M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-4.24M	-6.46M	-6.52M	-4.38M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	509	0	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-4.24M	-4.32M	333.76K	30.66M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.40M	-1.90M	-1.60M	-27.25M	-9.93M	-6.06M	-4.44M	-6.83M	-4.07M	-3.83M	-3.55M	-4.24M	-4.32M	333.76K	30.66M	-19.42M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-2.45	-0.27	-0.22	-1.80	3.19	-2.77
R&D Expense	-	-	0	323.50K	3.48M	1.41M	1.18M	2.00M	460.05K	301.22K	916.25K	690.94K	468.54K	407.43K	438.42K	391.30K

Balance Sheet (Annual)

Figures in USD.

Metric	Apr 2010	Apr 2011	Apr 2012	Apr 2013	Apr 2014	Apr 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025	Apr 2026
Total Assets	-	1.24M	2.09M	2.88M	9.32M	9.30M	7.16M	8.67M	6.41M	5.78M	6.17M	7.40M	90.62M	73.28M	59.90M	55.17M	46.75M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	85.49M	68.15M	50.44M	22.38M	-
Cash & Equivalents	716	57.20K	15.72K	199.30K	-	-	-	-	-	-	-	-	85.40M	68.04M	50.18M	15.17M	18.60M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3.70M	-
Total Liabilities	-	3.39M	3.79M	3.80M	373.67K	1.52M	637.64K	580.25K	644.17K	742.85K	1.08M	724.78K	704.37K	586.58K	20.39M	3.28M	11.77M
Current Liabilities	-	3.39M	3.79M	3.80M	373.67K	1.52M	637.64K	580.25K	644.17K	742.85K	1.03M	724.78K	704.37K	586.58K	7.42M	2.91M	826.42K
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Equity	-2.45M	-2.73M	-2.28M	-1.50M	8.94M	7.78M	6.52M	8.09M	5.77M	5.04M	5.09M	6.68M	89.92M	72.69M	39.51M	51.89M	33.29M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	20.72M	21.60M	21.67M	21.67M	-

Cash Flows (Annual)

Figures in USD.

Metric	Apr 2011	Apr 2012	Apr 2013	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025	Apr 2026
Operating Cash Flow	-225.23K	-259.29K	-390.43K	-3.34M	-5.08M	-2.88M	-2.34M	-3.33M	-4.12M	-3.79M	-2.15M	-2.98M	-5.15M
Investing Cash Flow	-	-871.73K	-646.75K	0	0	0	0	0	0	0	-5.00M	-7.00M	2.00M
Financing Cash Flow	281.72K	1.09M	1.22M	4.88M	2.68M	2.34M	2.73M	4.64M	87.31M	-13.56M	-10.71M	-25.03M	6.58M
Capital Expenditure	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-	-4.12M	-3.79M	-2.15M	-2.98M	-
Net Change in Cash	-	-	-	-	-	-	-	-	83.19M	-17.35M	-17.86M	-35.01M	-
Share Buybacks	-	-	-	-	-	-	-	-	0	13.56M	28.20M	2.54M	401.62K

Ratios (Annual)

Figures in %.

Metric	Apr 2011	Apr 2012	Apr 2013	Apr 2014	Apr 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025	Apr 2026
Gross Margin %	74.5%	70.9%	20.9%	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-2,928.5%	-13,851.7%	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin %	-1,109.3%	-2,853.6%	-13,142.3%	-	-	-	-	-	-	-	-	-	-	-	-	-
ROE %	51.2%	83.3%	106.4%	-304.8%	-127.7%	-93.0%	-54.9%	-118.4%	-80.7%	-75.2%	-53.2%	-4.7%	-5.9%	0.8%	59.1%	-58.3%
ROCE %	-	114.7%	182.8%	-212.2%	-170.5%	-93.1%	-54.9%	-121.0%	-81.4%	-74.5%	-54.2%	-4.9%	-8.9%	-12.4%	-8.4%	-14.9%

Shareholding Pattern

Insiders

5.74%

Institutions

7.11%

Public Float

7.54%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Geode Capital Management, LLC	0.01%	124.25K	$57.12K
2	Citadel Advisors Llc	0.01%	283.38K	$130.27K
3	Vanguard Capital Management LLC	-	56.78K	$26.10K
4	Renaissance Technologies, LLC	-	37.99K	$17.46K
5	Northern Trust Corporation	-	32.62K	$15.00K
6	Vanguard Fiduciary Trust Co	-	23.45K	$10.78K
7	Susquehanna International Group, LLP	-	44.85K	$20.62K
8	Xtx Topco Ltd	-	34.18K	$15.71K
9	Jane Street Group, LLC	-	30.06K	$13.82K
10	Schonfeld Strategic Advisors Llc	-	26.93K	$12.38K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PMCB

Google News Fri, 04 Sep 2026

Pharmacyt Biotch Stock Price Forecast. Should You Buy PMCB? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1xS0xQcGF4LV84dngxNlktUDFlLTRnLUwtcWFPZkRyOV9lZk12OGxOLWxfNkZwcGo5Q2dRZ01VSVVweW5jeE1CVQ?oc=5" target="_blank">Pharmacyt Biotch Stock Price Forecast. Should You Buy PMCB?</a> …

Google News Wed, 07 Jan 2026

Insider Purchase: CEO and President of $PMCB Buys 40,000 Shares | PMCB Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQaE5ZbC1PdTFNcmtQNnF4SWx2VEZ4dE5FQV9rVmtOZEtTMV82WEZ2X3Npa19mS1JmbXhBc29JN0FTcHVLRVRveldDdGZZMV9IMmFmam01Qk5LV1FqM1JMZ1ExeFItTnE1dVdicVJDLVVfV1ZwbzJJNW5qS3hwUWM2NjZTZXluTUxPRmswZ3…

Google News ue, 26 May 2026

PMCB - PharmaCyte Biotech Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBYb0ladVRaVTBUdlJTeXBXbFMzN2h5TUZ1MnE4NloxbTcyMW1sOEVMVktaSS1GdDlPT3RWbktfWjVJTjN1cnc?oc=5" target="_blank">PMCB - PharmaCyte Biotech Inc Stock Price and Quote</a>  <font…

Google News ue, 25 Nov 2025

PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOaVhHemV5UjdsaU11Z0poUDRkczkwdmdnbWY2NkZtTmpkbk5sQ1g1LUFnOXlRTThtUGU3NU9OS1U1aHQtOE9xMGVfNTQtSjN3Mkw3MHdNSi0zdDZPNXFwTHpoNk94ekhzZjZNaWRLdzhmRm96MUtBYWJRaU9GQW5fZmd1V2pSV0xtaTI0Tj…

Google News Fri, 07 Aug 2026

PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71% - Change of Character - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPRTgzX3VkVldMMnZKMXUxNjhYc1o2dkEtU05pLXFnN1cybFJsOVFwWkxHbTQ0MWt4ZW5MRHRqX2R4NFNfX0gwdVlDZ0g3ZWtoRmR3WEM1UGFGOFpoa0VoS0M4M1hGTU1PVGJsdnRRQ2gteGVJRGs5cXBWQllMVWZ0RGkyNnV6SEN1cVQ1SF…

Google News ue, 18 Aug 2026

PharmaCyte (PMCB) Share-Price Review: Slides 4.80% to $0.52 at the Close; Technical Focus: Price Remains Between $0.49 Support and $0.55 Resistance in the Current Update - Sign of Strength - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxQVEhZN0EtMWp0c00xM01CQjNiTF9HTlVJTFR5RnMxTmtMeGFjUUg0T2xuNThJZnJFejBMMWFWMFUwUUdUdy04TktJcHU3OFRqdzBOMVB6V0tLV2dBTlRFUjJqUnptV1AtS3JfanhWdHpmd3RadGFJRXpsWlJEeTBrUXZJUkVDd29VSE9BT1…

PMCB — Frequently Asked Questions

What is the current share price of PharmaCyte Biotech, Inc. (PMCB)?

As of 2026-09-19 21:16 PDT, PharmaCyte Biotech, Inc. (PMCB) trades at $0.49 on NasdaqCM. Its 52-week range is $0.48 to $1.22.

What is the market capitalisation of PMCB?

PharmaCyte Biotech, Inc. (PMCB) has a market capitalisation of $5.26M on NasdaqCM.

What is the P/E ratio of PMCB?

PMCB trades at a trailing price-to-earnings (P/E) ratio of -0.24. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.43.

What is the return on equity (ROE) of PMCB?

PMCB has a return on equity (ROE) of -43.99%. Its return on capital employed (ROCE) is -14.92%.

Is PMCB a good stock to buy?

This page provides a data-driven analysis of PharmaCyte Biotech, Inc. (PMCB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

PharmaCyte Biotech, Inc. PMCB PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Pharmacyt Biotch Stock Price Forecast. Should You Buy PMCB? - StockInvest.us

Insider Purchase: CEO and President of $PMCB Buys 40,000 Shares | PMCB Stock News - Quiver Quantitative

PMCB - PharmaCyte Biotech Inc Stock Price and Quote - Finviz

PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits

PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71% - Change of Character - vinanet.vn

PharmaCyte (PMCB) Share-Price Review: Slides 4.80% to $0.52 at the Close; Technical Focus: Price Remains Between $0.49 Support and $0.55 Resistance in the Current Update - Sign of Strength - dars.gov.et

PMCB — Frequently Asked Questions

What is the current share price of PharmaCyte Biotech, Inc. (PMCB)?

What is the market capitalisation of PMCB?

What is the P/E ratio of PMCB?

What is the return on equity (ROE) of PMCB?

Is PMCB a good stock to buy?

Explore More